Igniting the Future of Drug Discovery
AI-Powered Insights • Automation-Powered Genomics • Faster Results
Traditional Discovery Leaves Gaps
Traditional discovery services are expensive, require specialized expertise, and too often fail to deliver. The numbers tell the story: preclinical programs frequently fail due to inadequate target validation. False positives waste resources. And off-target effects continue to cause late-stage attrition.
The root cause? Inadequate mechanism of action characterization. Low confidence in on- and off-target validation. Siloed insights that never connect across discovery stages.
There's a better way.
One Platform. Complete Answers.
The Embyr Discovery Engine integrates knowledge graphs, deep probabilistic models, AI algorithms, and a modular CRISPR toolkit into a single, powerful platform. We don't just generate data—we deliver validated targets with complete mechanism insights.
Integrated platform
AI-driven workflows connect target prediction, functional validation, and mechanism reconstruction in a single, seamless process.
Functional Validation
Perturb-seq technology enables testing of hundreds of targets in parallel, providing statistical power to identify real hits.
Complete Mechanism Insight
Bayesian network reconstruction maps biological pathways, connecting perturbations to molecular mechanisms to outcomes.